SlideShare a Scribd company logo
Corporate Presentation 
December 2014
About Safeguard Scientifics (NYSE:SFE) 
> Founded in 1953 
> NYSE-listed since 1971 
> Proven Partner for entrepreneurs looking to accelerate growth and 
build long-term value in their businesses 
> Industry Focus on healthcare and technology 
> Successful Track Record includes $765M realized since 2006 
> Deep Domain Expertise as financiers and entrepreneurs 
> Strong Balance Sheet and Liquidity 
2
Why Own Safeguard (NYSE:SFE)? 
> Full Value Yet to be Realized or Recognized 
> Ownership Stakes in Exciting Partner Companies 
> Top Performance of Proven Team 
> Financial Strength, Flexibility and Liquidity 
> Strong Alignment of Interests 
3
Our Team 
4
Capital Deployment Objectives 
5
Pipeline Overview 
6 
1/1/14 through 9/30/14
Partner Companies By Sector 
* % represents allocation of capital deployed in current partner companies as of September 30, 2014. Safeguard has deployed a total of $233M in current partner companies. 
7
Partner Companies By Revenue Stage 
8
Partner Company Aggregate Revenue 
9
Partner Company Update: 
SEPT 2010 
Initial Capital 
Deployed 
$12.0M 
Total Capital Deployed 
1/100 
Babies born with a 
genetic disorder 
30% 
SFE Primary 
Ownership 
Med Tech 
Sector 
High 
Traction 
Revenue Stage 
> Molecular genetic information company 
> Genetic carrier screening tests based on 
next-generation sequencing technology 
> GoodStart SelectTM ― Screens for all 23 
genetic disorders recommended for 
screening by leading medical societies 
> Results in higher carrier detection rates 
regardless of ethnicity 
> Exclusive commercial partnership with 
PerkinElmer 
> Opportunity to expand tests beyond IVF 
(i.e. – OB/Gyn and maternal fetal 
medicine) 
10
Partner Company Update: 
> Global digital marketing operating 
system for agencies and enterprises 
> Pioneer in demand-side platform (DSP) 
> Raised more than $175M in equity and 
debt to fund global growth of its digital 
marketing operating system 
> 12 offices globally with 500+ employees 
> Serving 4500+ advertisers in 46 
countries 
> Projecting $100M+ software revenues 
(2014); EBITDA profitable since 2012 
JULY 2009 
Initial Capital 
Deployed 
$25.5M 
Total Capital Deployed 
$124B 
Digital advertising 
estimated CAGR 16% 
(2013-2017) 
21% 
SFE Primary 
Ownership 
Digital Media 
Sector 
High Traction 
Revenue Stage 
11
Partner Company Update: 
> Rapidly growing specialty 
pharmaceutical company 
> Developing high-quality, cost-effective 
generic medicines for pets 
> To date, commercialized 5 FDA-approved 
veterinary generic products in 
3 different dose forms 
> Projecting launch of up to 15 new 
products (2015-2017) 
> Approx. 240% revenue growth (2009- 
2013); projecting revenue by YE’18 of 
$190M and $40M+ EBITDA 
SEPT. 2011 
Initial Capital 
Deployed 
$14.9M 
Total Capital Deployed 
$2B 
Estimated market 
opportunity for generic 
pet prescriptions. 
28% 
SFE Primary 
Ownership 
Specialty 
Pharma 
Sector 
High 
Traction 
Revenue Stage 
12
Partner Company Holdings 
Acquisition 
Year 
Primary 
Ownership % 
Carrying 
Value Cost 
Healthcare Partner Companies: (in millions) (in millions) 
AdvantEdge Healthcare Solutions 2006 40% $ 5.5 $ 1 5.3 
Dabo Health 2013 13% 1.5 1.5 
Good Start Genetics 2010 30% 2.0 1 2.0 
InfoBionic 2014 18% 3.5 4.0 
Medivo 2011 35% 6.9 1 1.6 
NovaSom 2011 30% 8.3 2 1.1 
Propeller Health 2014 24% 9.0 9.0 
Putney 2011 28% 5 .4 1 4.9 
Quantia 2013 42% 8 .8 1 1.8 
Syapse 2014 27% 5.7 5.8 
Trice Medical 2014 32% 5.0 5.0 
TOTAL: 61.6 112.0 
Technology Partner Companies: 
AppFirst 2012 34% 5.3 8.6 
Apprenda 2013 22% 10.3 1 2.1 
Beyond.com 2007 38% 10.4 1 3.5 
Bridgevine 2007 17% 4.4 1 0.0 
Clutch 2013 30% 6.2 7.5 
DriveFactor 2011 41% 2.9 4.5 
Hoopla Software 2011 26% 1.3 3.1 
Lumesis 2012 49% 3.3 5.6 
MediaMath 2009 21% 20.3 2 5.5 
Pneuron 2013 28% 4.2 5.0 
Spongecell 2012 23% 8.8 1 0.0 
Transactis 2014 25% 9.5 9.5 
WebLinc 2014 29% 6.0 6.0 
TOTAL: 92.9 120.9 
Total: Healthcare + Technology $ 154.5 $ 232.9 
13
Success Stories 
14
Preliminary Cash Flow through 9/30/14 
(in millions) 
Beginning cash at 1/1/14 $ 183.7 
Sources: 
Exit proceeds 81.3 
Other 7.4 
Total Sources 88.7 
Uses: 
New partner company deployments 39.3 
Follow-on funding 25.3 
SFE stock buyback 25.0 
Corporate expenses - cash paid 14.9 
Interest 1.5 
Other 0.7 
Total Uses 106.7 
Ending cash at 9/30/14 $ 1 65.7 
15
NOLs and Capital Loss Carryforwards 
16
Equity Incentive Compensation 
> Key Goals 
• Structured to align with shareholder interest 
• Consistent with carried interest methodology 
• 75% of vesting based on performance criteria 
> Performance Vesting 
• Upon achievement of cash-on-cash return thresholds (2.4x-3.0x) on pools of capital 
deployed 
> Insider Ownership 
• 46% of outstanding grants are vested 
• Ownership requirements of 2x-4x base salary for senior management 
17
2014 Report Card 
As of 9/30/14 
18
2015 Goals and Objectives 
> Increase total number of partner companies to approximately 30 
> Realize continued growth in partner company aggregate revenue 
> Deploy $40M - $60M in new partner companies 
> Deploy $25M - $45M in follow-on funding for current partner companies 
> Continue to realize successful exits 
> Return excess cash to shareholders 
19
John E. Shave III 
SENIOR VICE PRESIDENT, 
INVESTOR RELATIONS & 
CORPORATE COMMUNICATIONS 
P 610.975.4952 
E jshave@safeguard.com 
20
Forward Looking Statements 
Statements contained in this presentation that are not historical facts are forward looking 
statements which involve certain risks and uncertainties including, but not limited to, risks 
associated with our ability to make good decisions about the deployment of capital, the 
fact that our partner companies may vary from period to period, our substantial capital 
requirements and absence of liquidity from our partner company holdings, fluctuations in 
the market prices of our publicly traded partner company holdings, competition, our 
inability to obtain maximum value for our partner company holdings, our ability to attract 
and retain qualified employees, market valuations in sectors in which our partner 
companies operate may decline, our inability to control our partner companies, our need to 
manage our assets to avoid registration under the Investment Company Act of 1940, and 
risks associated with our partner companies, and other uncertainties as described in our 
filings with the Securities and Exchange Commission, including our Annual Report on 
Form 10-K. Many of these factors are beyond our ability to predict or control. As a result of 
these and other factors, our past financial performance should not be relied on as an 
indication of future performance. 
Safeguard does not assume any obligation to update any forward looking statements or 
other information contained in this presentation. predicted or controlled. You should not 
rely on these statements as indicative of the partner company’s future results, and all 
forward looking statements are qualified by this cautionary statement. All information is as 
of the date indicated or as of the date of this presentation, and none of the partner 
companies assumes any obligation to update or revise the information presented. 
21

More Related Content

What's hot

Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - December ...
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - December ...Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - December ...
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - December ...
Safeguard Scientifics
 
November Investor Presentation
November Investor PresentationNovember Investor Presentation
November Investor Presentation
Devon Energy Corporation
 
IFC investor presentation sept 19, 2011
IFC investor presentation sept 19, 2011IFC investor presentation sept 19, 2011
IFC investor presentation sept 19, 2011
mehradahari
 
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - February ...
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - February ...Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - February ...
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - February ...
Safeguard Scientifics
 
quest diagnostics q1 2005
quest diagnostics q1 2005quest diagnostics q1 2005
quest diagnostics q1 2005
finance34
 
Investor Presentation April 2015
Investor Presentation April 2015Investor Presentation April 2015
Investor Presentation April 2015
Intact
 
Investor Presentation for December 2015
Investor Presentation for December 2015Investor Presentation for December 2015
Investor Presentation for December 2015
Intact
 
Investor Presentation September 2014
Investor Presentation September 2014 Investor Presentation September 2014
Investor Presentation September 2014
Intact
 
Jefferies 2015 final
Jefferies 2015 finalJefferies 2015 final
Jefferies 2015 final
Valeant_Pharmaceuticals
 
Alembic Pharma Q1FY15: EBITDA margins improved by ~285 bps y-o-y; Hold
 Alembic Pharma Q1FY15: EBITDA margins improved by ~285 bps y-o-y; Hold Alembic Pharma Q1FY15: EBITDA margins improved by ~285 bps y-o-y; Hold
Alembic Pharma Q1FY15: EBITDA margins improved by ~285 bps y-o-y; Hold
IndiaNotes.com
 
20150218 investor document 4 q final2
20150218 investor document 4 q final220150218 investor document 4 q final2
20150218 investor document 4 q final2
Valeant_Pharmaceuticals
 
Csod investor deck third quarter fina lv2
Csod investor deck third quarter   fina lv2Csod investor deck third quarter   fina lv2
Csod investor deck third quarter fina lv2
ircornerstone
 
4 q final 2 (4)
4 q final 2 (4)4 q final 2 (4)
4 q final 2 (4)
Valeant_Pharmaceuticals
 
Investor presentation-august-2015
Investor presentation-august-2015Investor presentation-august-2015
Investor presentation-august-2015
Intact
 
Nvta q1 18 earnings deck final
Nvta q1 18 earnings deck finalNvta q1 18 earnings deck final
Nvta q1 18 earnings deck final
invitaeir
 
Valeant allergan investor presentation final
Valeant allergan investor presentation finalValeant allergan investor presentation final
Valeant allergan investor presentation final
Valeant_Pharmaceuticals
 
Q22015 earnings deck final
Q22015 earnings deck finalQ22015 earnings deck final
Q22015 earnings deck final
Valeant_Pharmaceuticals
 
Investor Conference Call October 26, 2015
Investor Conference Call October 26, 2015Investor Conference Call October 26, 2015
Investor Conference Call October 26, 2015
Valeant_Pharmaceuticals
 
Ifc investor-presentation-(september-2016)
Ifc investor-presentation-(september-2016)Ifc investor-presentation-(september-2016)
Ifc investor-presentation-(september-2016)
Intact
 
Valeant Pharmaceuticals 2015 Annual Shareholders Meeting
Valeant Pharmaceuticals 2015 Annual Shareholders MeetingValeant Pharmaceuticals 2015 Annual Shareholders Meeting
Valeant Pharmaceuticals 2015 Annual Shareholders Meeting
Valeant_Pharmaceuticals
 

What's hot (20)

Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - December ...
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - December ...Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - December ...
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - December ...
 
November Investor Presentation
November Investor PresentationNovember Investor Presentation
November Investor Presentation
 
IFC investor presentation sept 19, 2011
IFC investor presentation sept 19, 2011IFC investor presentation sept 19, 2011
IFC investor presentation sept 19, 2011
 
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - February ...
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - February ...Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - February ...
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - February ...
 
quest diagnostics q1 2005
quest diagnostics q1 2005quest diagnostics q1 2005
quest diagnostics q1 2005
 
Investor Presentation April 2015
Investor Presentation April 2015Investor Presentation April 2015
Investor Presentation April 2015
 
Investor Presentation for December 2015
Investor Presentation for December 2015Investor Presentation for December 2015
Investor Presentation for December 2015
 
Investor Presentation September 2014
Investor Presentation September 2014 Investor Presentation September 2014
Investor Presentation September 2014
 
Jefferies 2015 final
Jefferies 2015 finalJefferies 2015 final
Jefferies 2015 final
 
Alembic Pharma Q1FY15: EBITDA margins improved by ~285 bps y-o-y; Hold
 Alembic Pharma Q1FY15: EBITDA margins improved by ~285 bps y-o-y; Hold Alembic Pharma Q1FY15: EBITDA margins improved by ~285 bps y-o-y; Hold
Alembic Pharma Q1FY15: EBITDA margins improved by ~285 bps y-o-y; Hold
 
20150218 investor document 4 q final2
20150218 investor document 4 q final220150218 investor document 4 q final2
20150218 investor document 4 q final2
 
Csod investor deck third quarter fina lv2
Csod investor deck third quarter   fina lv2Csod investor deck third quarter   fina lv2
Csod investor deck third quarter fina lv2
 
4 q final 2 (4)
4 q final 2 (4)4 q final 2 (4)
4 q final 2 (4)
 
Investor presentation-august-2015
Investor presentation-august-2015Investor presentation-august-2015
Investor presentation-august-2015
 
Nvta q1 18 earnings deck final
Nvta q1 18 earnings deck finalNvta q1 18 earnings deck final
Nvta q1 18 earnings deck final
 
Valeant allergan investor presentation final
Valeant allergan investor presentation finalValeant allergan investor presentation final
Valeant allergan investor presentation final
 
Q22015 earnings deck final
Q22015 earnings deck finalQ22015 earnings deck final
Q22015 earnings deck final
 
Investor Conference Call October 26, 2015
Investor Conference Call October 26, 2015Investor Conference Call October 26, 2015
Investor Conference Call October 26, 2015
 
Ifc investor-presentation-(september-2016)
Ifc investor-presentation-(september-2016)Ifc investor-presentation-(september-2016)
Ifc investor-presentation-(september-2016)
 
Valeant Pharmaceuticals 2015 Annual Shareholders Meeting
Valeant Pharmaceuticals 2015 Annual Shareholders MeetingValeant Pharmaceuticals 2015 Annual Shareholders Meeting
Valeant Pharmaceuticals 2015 Annual Shareholders Meeting
 

Viewers also liked

Safeguard Scientifics Corporate Presentation - April 2015
Safeguard Scientifics Corporate Presentation - April 2015Safeguard Scientifics Corporate Presentation - April 2015
Safeguard Scientifics Corporate Presentation - April 2015
Safeguard Scientifics
 
Safeguard Scientifics Corporate Presentation - April 24, 2015
Safeguard Scientifics Corporate Presentation - April 24, 2015Safeguard Scientifics Corporate Presentation - April 24, 2015
Safeguard Scientifics Corporate Presentation - April 24, 2015
Safeguard Scientifics
 
Safeguard Scientifics Corporate Presentation - June 2015
Safeguard Scientifics Corporate Presentation - June 2015Safeguard Scientifics Corporate Presentation - June 2015
Safeguard Scientifics Corporate Presentation - June 2015
Safeguard Scientifics
 
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - October 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - October 2012Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - October 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - October 2012
Safeguard Scientifics
 
Safeguard Scientifics Corporate Presentation - January 2015
Safeguard Scientifics Corporate Presentation - January 2015Safeguard Scientifics Corporate Presentation - January 2015
Safeguard Scientifics Corporate Presentation - January 2015
Safeguard Scientifics
 
Safeguard Scientifics Corporate Presentation - May 2015
Safeguard Scientifics Corporate Presentation - May 2015Safeguard Scientifics Corporate Presentation - May 2015
Safeguard Scientifics Corporate Presentation - May 2015
Safeguard Scientifics
 
Safeguard Scientifics Corporate Presentation - March 2015
Safeguard Scientifics Corporate Presentation - March 2015Safeguard Scientifics Corporate Presentation - March 2015
Safeguard Scientifics Corporate Presentation - March 2015
Safeguard Scientifics
 
Safeguard Scientifics Corporate Presentation - July 2015
Safeguard Scientifics Corporate Presentation - July 2015Safeguard Scientifics Corporate Presentation - July 2015
Safeguard Scientifics Corporate Presentation - July 2015
Safeguard Scientifics
 

Viewers also liked (8)

Safeguard Scientifics Corporate Presentation - April 2015
Safeguard Scientifics Corporate Presentation - April 2015Safeguard Scientifics Corporate Presentation - April 2015
Safeguard Scientifics Corporate Presentation - April 2015
 
Safeguard Scientifics Corporate Presentation - April 24, 2015
Safeguard Scientifics Corporate Presentation - April 24, 2015Safeguard Scientifics Corporate Presentation - April 24, 2015
Safeguard Scientifics Corporate Presentation - April 24, 2015
 
Safeguard Scientifics Corporate Presentation - June 2015
Safeguard Scientifics Corporate Presentation - June 2015Safeguard Scientifics Corporate Presentation - June 2015
Safeguard Scientifics Corporate Presentation - June 2015
 
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - October 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - October 2012Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - October 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - October 2012
 
Safeguard Scientifics Corporate Presentation - January 2015
Safeguard Scientifics Corporate Presentation - January 2015Safeguard Scientifics Corporate Presentation - January 2015
Safeguard Scientifics Corporate Presentation - January 2015
 
Safeguard Scientifics Corporate Presentation - May 2015
Safeguard Scientifics Corporate Presentation - May 2015Safeguard Scientifics Corporate Presentation - May 2015
Safeguard Scientifics Corporate Presentation - May 2015
 
Safeguard Scientifics Corporate Presentation - March 2015
Safeguard Scientifics Corporate Presentation - March 2015Safeguard Scientifics Corporate Presentation - March 2015
Safeguard Scientifics Corporate Presentation - March 2015
 
Safeguard Scientifics Corporate Presentation - July 2015
Safeguard Scientifics Corporate Presentation - July 2015Safeguard Scientifics Corporate Presentation - July 2015
Safeguard Scientifics Corporate Presentation - July 2015
 

Similar to Corporate Presentation - December 2014

Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - March 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - March 2012Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - March 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - March 2012
Safeguard Scientifics
 
Jpm 2015 final2
Jpm 2015 final2Jpm 2015 final2
Jpm 2015 final2
Valeant_Pharmaceuticals
 
Safeguard Scientifics (NYSE:SFE) Corporate Presentation - March 2014
Safeguard Scientifics (NYSE:SFE) Corporate Presentation - March 2014Safeguard Scientifics (NYSE:SFE) Corporate Presentation - March 2014
Safeguard Scientifics (NYSE:SFE) Corporate Presentation - March 2014
Safeguard Scientifics
 
Safeguard Scientifics (NYSE:SFE) Corporate Presentation - June 2014
Safeguard Scientifics (NYSE:SFE) Corporate Presentation - June 2014Safeguard Scientifics (NYSE:SFE) Corporate Presentation - June 2014
Safeguard Scientifics (NYSE:SFE) Corporate Presentation - June 2014
Safeguard Scientifics
 
Pinnacle Foods Inc. Presentation to CAGNY
Pinnacle Foods Inc. Presentation to CAGNYPinnacle Foods Inc. Presentation to CAGNY
Pinnacle Foods Inc. Presentation to CAGNY
pinnaclefood
 
10.25.12 sfe q3 2012 results presentation final
10.25.12 sfe q3 2012 results   presentation final10.25.12 sfe q3 2012 results   presentation final
10.25.12 sfe q3 2012 results presentation final
Safeguard Scientifics
 
Safeguard Scientifics (NYSE:SFE) Corporate Presentation - December 2013
Safeguard Scientifics (NYSE:SFE) Corporate Presentation - December 2013Safeguard Scientifics (NYSE:SFE) Corporate Presentation - December 2013
Safeguard Scientifics (NYSE:SFE) Corporate Presentation - December 2013
Safeguard Scientifics
 
2014 08 20 investor presentation (en)
2014 08 20   investor presentation (en)2014 08 20   investor presentation (en)
2014 08 20 investor presentation (en)
Multiplus
 
capartners.com-capflash-issue70
capartners.com-capflash-issue70capartners.com-capflash-issue70
capartners.com-capflash-issue70
Hannah Liu
 
Q4 Earnings Presentation V2
Q4 Earnings Presentation V2Q4 Earnings Presentation V2
Q4 Earnings Presentation V2
Moelis_Company
 
Q4 2018 Earnings Presentation
Q4 2018 Earnings PresentationQ4 2018 Earnings Presentation
Q4 2018 Earnings Presentation
Moelis_Company
 
Moelis company april investor pres_vfinal2
Moelis  company april investor pres_vfinal2Moelis  company april investor pres_vfinal2
Moelis company april investor pres_vfinal2
Moelis_Company
 
Moelis company april investor pres_vfinal3
Moelis  company april investor pres_vfinal3Moelis  company april investor pres_vfinal3
Moelis company april investor pres_vfinal3
Moelis_Company
 
2014 itw annual_report
2014 itw annual_report2014 itw annual_report
2014 itw annual_report
ismail ekmekci
 
Moelis Company April Investor Presentation
Moelis Company April Investor PresentationMoelis Company April Investor Presentation
Moelis Company April Investor Presentation
Moelis_Company
 
STRATEGIC GUIDE FOR INCREASING PROFITS.pptx
STRATEGIC GUIDE FOR INCREASING PROFITS.pptxSTRATEGIC GUIDE FOR INCREASING PROFITS.pptx
STRATEGIC GUIDE FOR INCREASING PROFITS.pptx
ChoolanieMayadunne
 
Moelis Company July Investor Presentation
Moelis Company July Investor PresentationMoelis Company July Investor Presentation
Moelis Company July Investor Presentation
Moelis_Company
 
Atento Q4FY14 Bondholders Presentation
Atento Q4FY14 Bondholders PresentationAtento Q4FY14 Bondholders Presentation
Atento Q4FY14 Bondholders Presentation
investorsatento
 
Moelis Company - Q3 Investor Presentation
Moelis Company - Q3 Investor PresentationMoelis Company - Q3 Investor Presentation
Moelis Company - Q3 Investor Presentation
Moelis_Company
 
1001205101
10012051011001205101
1001205101
veriskir
 

Similar to Corporate Presentation - December 2014 (20)

Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - March 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - March 2012Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - March 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - March 2012
 
Jpm 2015 final2
Jpm 2015 final2Jpm 2015 final2
Jpm 2015 final2
 
Safeguard Scientifics (NYSE:SFE) Corporate Presentation - March 2014
Safeguard Scientifics (NYSE:SFE) Corporate Presentation - March 2014Safeguard Scientifics (NYSE:SFE) Corporate Presentation - March 2014
Safeguard Scientifics (NYSE:SFE) Corporate Presentation - March 2014
 
Safeguard Scientifics (NYSE:SFE) Corporate Presentation - June 2014
Safeguard Scientifics (NYSE:SFE) Corporate Presentation - June 2014Safeguard Scientifics (NYSE:SFE) Corporate Presentation - June 2014
Safeguard Scientifics (NYSE:SFE) Corporate Presentation - June 2014
 
Pinnacle Foods Inc. Presentation to CAGNY
Pinnacle Foods Inc. Presentation to CAGNYPinnacle Foods Inc. Presentation to CAGNY
Pinnacle Foods Inc. Presentation to CAGNY
 
10.25.12 sfe q3 2012 results presentation final
10.25.12 sfe q3 2012 results   presentation final10.25.12 sfe q3 2012 results   presentation final
10.25.12 sfe q3 2012 results presentation final
 
Safeguard Scientifics (NYSE:SFE) Corporate Presentation - December 2013
Safeguard Scientifics (NYSE:SFE) Corporate Presentation - December 2013Safeguard Scientifics (NYSE:SFE) Corporate Presentation - December 2013
Safeguard Scientifics (NYSE:SFE) Corporate Presentation - December 2013
 
2014 08 20 investor presentation (en)
2014 08 20   investor presentation (en)2014 08 20   investor presentation (en)
2014 08 20 investor presentation (en)
 
capartners.com-capflash-issue70
capartners.com-capflash-issue70capartners.com-capflash-issue70
capartners.com-capflash-issue70
 
Q4 Earnings Presentation V2
Q4 Earnings Presentation V2Q4 Earnings Presentation V2
Q4 Earnings Presentation V2
 
Q4 2018 Earnings Presentation
Q4 2018 Earnings PresentationQ4 2018 Earnings Presentation
Q4 2018 Earnings Presentation
 
Moelis company april investor pres_vfinal2
Moelis  company april investor pres_vfinal2Moelis  company april investor pres_vfinal2
Moelis company april investor pres_vfinal2
 
Moelis company april investor pres_vfinal3
Moelis  company april investor pres_vfinal3Moelis  company april investor pres_vfinal3
Moelis company april investor pres_vfinal3
 
2014 itw annual_report
2014 itw annual_report2014 itw annual_report
2014 itw annual_report
 
Moelis Company April Investor Presentation
Moelis Company April Investor PresentationMoelis Company April Investor Presentation
Moelis Company April Investor Presentation
 
STRATEGIC GUIDE FOR INCREASING PROFITS.pptx
STRATEGIC GUIDE FOR INCREASING PROFITS.pptxSTRATEGIC GUIDE FOR INCREASING PROFITS.pptx
STRATEGIC GUIDE FOR INCREASING PROFITS.pptx
 
Moelis Company July Investor Presentation
Moelis Company July Investor PresentationMoelis Company July Investor Presentation
Moelis Company July Investor Presentation
 
Atento Q4FY14 Bondholders Presentation
Atento Q4FY14 Bondholders PresentationAtento Q4FY14 Bondholders Presentation
Atento Q4FY14 Bondholders Presentation
 
Moelis Company - Q3 Investor Presentation
Moelis Company - Q3 Investor PresentationMoelis Company - Q3 Investor Presentation
Moelis Company - Q3 Investor Presentation
 
1001205101
10012051011001205101
1001205101
 

More from Safeguard Scientifics

Safeguard Scientifics (NYSE:SFE) Corporate Presentation - November 2013
Safeguard Scientifics (NYSE:SFE) Corporate Presentation - November 2013Safeguard Scientifics (NYSE:SFE) Corporate Presentation - November 2013
Safeguard Scientifics (NYSE:SFE) Corporate Presentation - November 2013
Safeguard Scientifics
 
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - December ...
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - December ...Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - December ...
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - December ...
Safeguard Scientifics
 
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - November ...
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - November ...Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - November ...
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - November ...
Safeguard Scientifics
 
Safeguard Scientifics Third Quarter 2012 Financial Results Presentation
Safeguard Scientifics Third Quarter 2012 Financial Results PresentationSafeguard Scientifics Third Quarter 2012 Financial Results Presentation
Safeguard Scientifics Third Quarter 2012 Financial Results Presentation
Safeguard Scientifics
 
Anatomy of a Deal: Avid Radiopharmaceuticals
Anatomy of a Deal: Avid RadiopharmaceuticalsAnatomy of a Deal: Avid Radiopharmaceuticals
Anatomy of a Deal: Avid Radiopharmaceuticals
Safeguard Scientifics
 
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - September...
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - September...Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - September...
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - September...
Safeguard Scientifics
 
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - August 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - August 2012Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - August 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - August 2012
Safeguard Scientifics
 
Safeguard Scientifics Second Quarter 2012 Financial Results Presentation
Safeguard Scientifics Second Quarter 2012 Financial Results PresentationSafeguard Scientifics Second Quarter 2012 Financial Results Presentation
Safeguard Scientifics Second Quarter 2012 Financial Results Presentation
Safeguard Scientifics
 
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - July 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - July 2012Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - July 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - July 2012
Safeguard Scientifics
 
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - June 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - June 2012Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - June 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - June 2012
Safeguard Scientifics
 
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - May 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - May 2012 Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - May 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - May 2012
Safeguard Scientifics
 
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - April 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - April 2012Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - April 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - April 2012
Safeguard Scientifics
 
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - January 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - January 2012Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - January 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - January 2012
Safeguard Scientifics
 
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - January 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - January 2012Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - January 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - January 2012
Safeguard Scientifics
 

More from Safeguard Scientifics (14)

Safeguard Scientifics (NYSE:SFE) Corporate Presentation - November 2013
Safeguard Scientifics (NYSE:SFE) Corporate Presentation - November 2013Safeguard Scientifics (NYSE:SFE) Corporate Presentation - November 2013
Safeguard Scientifics (NYSE:SFE) Corporate Presentation - November 2013
 
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - December ...
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - December ...Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - December ...
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - December ...
 
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - November ...
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - November ...Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - November ...
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - November ...
 
Safeguard Scientifics Third Quarter 2012 Financial Results Presentation
Safeguard Scientifics Third Quarter 2012 Financial Results PresentationSafeguard Scientifics Third Quarter 2012 Financial Results Presentation
Safeguard Scientifics Third Quarter 2012 Financial Results Presentation
 
Anatomy of a Deal: Avid Radiopharmaceuticals
Anatomy of a Deal: Avid RadiopharmaceuticalsAnatomy of a Deal: Avid Radiopharmaceuticals
Anatomy of a Deal: Avid Radiopharmaceuticals
 
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - September...
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - September...Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - September...
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - September...
 
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - August 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - August 2012Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - August 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - August 2012
 
Safeguard Scientifics Second Quarter 2012 Financial Results Presentation
Safeguard Scientifics Second Quarter 2012 Financial Results PresentationSafeguard Scientifics Second Quarter 2012 Financial Results Presentation
Safeguard Scientifics Second Quarter 2012 Financial Results Presentation
 
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - July 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - July 2012Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - July 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - July 2012
 
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - June 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - June 2012Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - June 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - June 2012
 
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - May 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - May 2012 Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - May 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - May 2012
 
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - April 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - April 2012Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - April 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - April 2012
 
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - January 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - January 2012Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - January 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - January 2012
 
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - January 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - January 2012Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - January 2012
Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - January 2012
 

Corporate Presentation - December 2014

  • 2. About Safeguard Scientifics (NYSE:SFE) > Founded in 1953 > NYSE-listed since 1971 > Proven Partner for entrepreneurs looking to accelerate growth and build long-term value in their businesses > Industry Focus on healthcare and technology > Successful Track Record includes $765M realized since 2006 > Deep Domain Expertise as financiers and entrepreneurs > Strong Balance Sheet and Liquidity 2
  • 3. Why Own Safeguard (NYSE:SFE)? > Full Value Yet to be Realized or Recognized > Ownership Stakes in Exciting Partner Companies > Top Performance of Proven Team > Financial Strength, Flexibility and Liquidity > Strong Alignment of Interests 3
  • 6. Pipeline Overview 6 1/1/14 through 9/30/14
  • 7. Partner Companies By Sector * % represents allocation of capital deployed in current partner companies as of September 30, 2014. Safeguard has deployed a total of $233M in current partner companies. 7
  • 8. Partner Companies By Revenue Stage 8
  • 10. Partner Company Update: SEPT 2010 Initial Capital Deployed $12.0M Total Capital Deployed 1/100 Babies born with a genetic disorder 30% SFE Primary Ownership Med Tech Sector High Traction Revenue Stage > Molecular genetic information company > Genetic carrier screening tests based on next-generation sequencing technology > GoodStart SelectTM ― Screens for all 23 genetic disorders recommended for screening by leading medical societies > Results in higher carrier detection rates regardless of ethnicity > Exclusive commercial partnership with PerkinElmer > Opportunity to expand tests beyond IVF (i.e. – OB/Gyn and maternal fetal medicine) 10
  • 11. Partner Company Update: > Global digital marketing operating system for agencies and enterprises > Pioneer in demand-side platform (DSP) > Raised more than $175M in equity and debt to fund global growth of its digital marketing operating system > 12 offices globally with 500+ employees > Serving 4500+ advertisers in 46 countries > Projecting $100M+ software revenues (2014); EBITDA profitable since 2012 JULY 2009 Initial Capital Deployed $25.5M Total Capital Deployed $124B Digital advertising estimated CAGR 16% (2013-2017) 21% SFE Primary Ownership Digital Media Sector High Traction Revenue Stage 11
  • 12. Partner Company Update: > Rapidly growing specialty pharmaceutical company > Developing high-quality, cost-effective generic medicines for pets > To date, commercialized 5 FDA-approved veterinary generic products in 3 different dose forms > Projecting launch of up to 15 new products (2015-2017) > Approx. 240% revenue growth (2009- 2013); projecting revenue by YE’18 of $190M and $40M+ EBITDA SEPT. 2011 Initial Capital Deployed $14.9M Total Capital Deployed $2B Estimated market opportunity for generic pet prescriptions. 28% SFE Primary Ownership Specialty Pharma Sector High Traction Revenue Stage 12
  • 13. Partner Company Holdings Acquisition Year Primary Ownership % Carrying Value Cost Healthcare Partner Companies: (in millions) (in millions) AdvantEdge Healthcare Solutions 2006 40% $ 5.5 $ 1 5.3 Dabo Health 2013 13% 1.5 1.5 Good Start Genetics 2010 30% 2.0 1 2.0 InfoBionic 2014 18% 3.5 4.0 Medivo 2011 35% 6.9 1 1.6 NovaSom 2011 30% 8.3 2 1.1 Propeller Health 2014 24% 9.0 9.0 Putney 2011 28% 5 .4 1 4.9 Quantia 2013 42% 8 .8 1 1.8 Syapse 2014 27% 5.7 5.8 Trice Medical 2014 32% 5.0 5.0 TOTAL: 61.6 112.0 Technology Partner Companies: AppFirst 2012 34% 5.3 8.6 Apprenda 2013 22% 10.3 1 2.1 Beyond.com 2007 38% 10.4 1 3.5 Bridgevine 2007 17% 4.4 1 0.0 Clutch 2013 30% 6.2 7.5 DriveFactor 2011 41% 2.9 4.5 Hoopla Software 2011 26% 1.3 3.1 Lumesis 2012 49% 3.3 5.6 MediaMath 2009 21% 20.3 2 5.5 Pneuron 2013 28% 4.2 5.0 Spongecell 2012 23% 8.8 1 0.0 Transactis 2014 25% 9.5 9.5 WebLinc 2014 29% 6.0 6.0 TOTAL: 92.9 120.9 Total: Healthcare + Technology $ 154.5 $ 232.9 13
  • 15. Preliminary Cash Flow through 9/30/14 (in millions) Beginning cash at 1/1/14 $ 183.7 Sources: Exit proceeds 81.3 Other 7.4 Total Sources 88.7 Uses: New partner company deployments 39.3 Follow-on funding 25.3 SFE stock buyback 25.0 Corporate expenses - cash paid 14.9 Interest 1.5 Other 0.7 Total Uses 106.7 Ending cash at 9/30/14 $ 1 65.7 15
  • 16. NOLs and Capital Loss Carryforwards 16
  • 17. Equity Incentive Compensation > Key Goals • Structured to align with shareholder interest • Consistent with carried interest methodology • 75% of vesting based on performance criteria > Performance Vesting • Upon achievement of cash-on-cash return thresholds (2.4x-3.0x) on pools of capital deployed > Insider Ownership • 46% of outstanding grants are vested • Ownership requirements of 2x-4x base salary for senior management 17
  • 18. 2014 Report Card As of 9/30/14 18
  • 19. 2015 Goals and Objectives > Increase total number of partner companies to approximately 30 > Realize continued growth in partner company aggregate revenue > Deploy $40M - $60M in new partner companies > Deploy $25M - $45M in follow-on funding for current partner companies > Continue to realize successful exits > Return excess cash to shareholders 19
  • 20. John E. Shave III SENIOR VICE PRESIDENT, INVESTOR RELATIONS & CORPORATE COMMUNICATIONS P 610.975.4952 E jshave@safeguard.com 20
  • 21. Forward Looking Statements Statements contained in this presentation that are not historical facts are forward looking statements which involve certain risks and uncertainties including, but not limited to, risks associated with our ability to make good decisions about the deployment of capital, the fact that our partner companies may vary from period to period, our substantial capital requirements and absence of liquidity from our partner company holdings, fluctuations in the market prices of our publicly traded partner company holdings, competition, our inability to obtain maximum value for our partner company holdings, our ability to attract and retain qualified employees, market valuations in sectors in which our partner companies operate may decline, our inability to control our partner companies, our need to manage our assets to avoid registration under the Investment Company Act of 1940, and risks associated with our partner companies, and other uncertainties as described in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. Many of these factors are beyond our ability to predict or control. As a result of these and other factors, our past financial performance should not be relied on as an indication of future performance. Safeguard does not assume any obligation to update any forward looking statements or other information contained in this presentation. predicted or controlled. You should not rely on these statements as indicative of the partner company’s future results, and all forward looking statements are qualified by this cautionary statement. All information is as of the date indicated or as of the date of this presentation, and none of the partner companies assumes any obligation to update or revise the information presented. 21